{"name":"Turning Point Therapeutics, Inc.","slug":"turning-point-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNVWtoY2JjN2JNT2tNQ21nYkFmVGRxRmllU3M3Z2dJcU9HZEVpcmpGUVl6NlVUdGtFSV9lVFJkSnNfdTdENG1fQmxzU2dPTVpXc1U4QThhbl9WanV1WDkxOUZOM0djR0p4UEY1MFRiZVlFYTRRZURTYTFwRVVDVmdQekt6aHZHYXNZem9HYk10eGxpUkZPdjlkOVJLLWhySXc1a1VORGJvYjFRdWlzSlo5V3VtV1BxdE9SZldoRmNB?oc=5","date":"2026-03-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"Huntington’s gene therapy research has reached a turning point, expert says - Pharmaceutical Technology","headline":"Huntington’s gene therapy research has reached a turning point, expert says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQbTZUamk1azNheEg5WDdJTHZDSXMzMTdKTWRaOVRZazhjVFRUUzNGWFhHMDhEOXJHQ0xTaThuYXRxb1gzc3Q5OWtHVkZnWnZIS0cxX3NXTjFjdnB4LTdBR1k0aDJFSnlyUmZSZ1M2RDRSU25zeUI3Uy04TS1CZ2wwT2g3M0RYMWxCc3F6ai1hTEllNTRDTUpibWZDdWxUV0ZDUTJxamt3S3A4bktNNW56XzVnaElHTHNDMUNpVnpuRHpaVW0y?oc=5","date":"2026-03-09","type":"pipeline","source":"AD HOC NEWS","summary":"Telix Pharmaceuticals: A Potential Turning Point for the Radiopharma Specialist - AD HOC NEWS","headline":"Telix Pharmaceuticals: A Potential Turning Point for the Radiopharma Specialist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBYR1d4bWh1ejJoanlmeGstQktPeXVEeHJhTXlEVjBxRlh0NjNGcC1rYnR2UThEdmdpdVpCcFlWQWQzZTBsQjJGVlB3QWJ4NVQyZF9zYnIyZWRSdFBIUXdN?oc=5","date":"2026-02-04","type":"trial","source":"nature.com","summary":"Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial - nature.com","headline":"Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNXzhCWEJsY2owbGhpaEl4djZvbWU2QTV0elFrMFExc3o0V2FkXzhRV2VIRlZtdDBMYTVpNVFlVXVscGdMNFV0eTVNUjFIVmlxLWF6ZXB2dHUyUHpwVmZUMThwRHJ5TDZPRklIVTVsc0JvNVVieTVLSE5YUG5tTF9OeWt4Zmh6UVJFdWI3VmZWMmVtWUktbVdMX1FlOWdCcUF0WjdUZzZ4bFFfUQ?oc=5","date":"2025-12-31","type":"pipeline","source":"BioWorld News","summary":"Blossomhill advancing EGFR, CLK inhibitors with series B extension - BioWorld News","headline":"Blossomhill advancing EGFR, CLK inhibitors with series B extension","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPamF6MGp2a3V0MF84RVdvQWRCTEdSRHNEa2pKa19lR1FoREpXZHc1YW10VFJIQ0ppeV9ra2pGZ3E4WFZuQjdvWkV1V1plTU40QlFVSVNBZ3hDVEpKMkNySWVGT1JScFNuRFIwaWFxRjh6MGFIaEZrSzlzMXNwZmpnUW5oVmFGYUE0MGF0WUlrdlFZRVlBNE5pUnR4RnlhSTg4a0xFVG15dno1Umw3VXBwTlFVLW44ZVJ6NmlYektyY0RjN1ktc2pnQ2ZxNWp2UGctazdPSTktc00yOVhXRjJKV3BYcnpZakZsRGfSAe8BQVVfeXFMT0tESXhhTHZDN0FSYnU5RUFSWDVKQ19qQ3Rsb2plQ2UtdC1nbkpFYXF2ajJydjZmdnotUFNYZUx5TnNEeHFGakZ3c21yYzdUTlMwN1RlbXBUa0pacXlKeFVnb1A2REFKRUpja0RnUVZlUnhpS3h6VGFHY0RSZVVTQXFZNFNiSXBvZTJieHVWRjRHdUpLaEowTkd5T08tZEFlYU04dlJoTWVNMmlsbUV3cVdZbVpIZG5XMUxDdDZ1cEVJWjVycFB4MGhLYlVIYllmX3lTTXRpOXQ3M3BwZXg2RzR0bDh6M1RSTTB5QVE2U1E?oc=5","date":"2025-11-14","type":"pipeline","source":"simplywall.st","summary":"Are Applied Therapeutics' (APLT) Narrowing Losses a Turning Point for Its Strategic Vision? - simplywall.st","headline":"Are Applied Therapeutics' (APLT) Narrowing Losses a Turning Point for Its Strategic Vision?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxPOHlrWnQ0OUZrZXdEWVY4blZYZmd0V3M4X1dtN09YYVlhazhCMkFUbzZfLTZGMHZ0Nmk1Tmp0b24wdnRIQnZSVDNMQTljeUZ3VlFhRlB0emUwbkhjX3p5LV9ZMDVEckhwREEyVTdwMWpXQk5zMGs2RkJ0VXZyYUhVZUIxUHd4UXZsM3U3aFJ5bFJZSGNjNEhSUlRtMWtCNF83WWhMR0ZGZmVwZ1JUR3VmeDRmb3gxX1U2dHA2bndnRjhHQkc5aEJ0ekUyYjh6bS1lUlBIZ2d2QUh5cnREV0lmcnBXMTQ3RVJfS2xuMjRvam1seDVyT1hESlRSSG5leS1Ec0JVbzJueFQ4aVZtRC05M3NqRmpkQ1l5VFBsb2xOc25aS2ZpbThJTzdRUQ?oc=5","date":"2025-05-02","type":"pipeline","source":"Buchanan Ingersoll & Rooney","summary":"A Blueprint for Action: Michigan’s Lawsuit Against Express Scripts and Prime Therapeutics Signals a Turning Point for Independent Pharmacies, Plan Sponsor, Patients, and State Enforcement - Buchanan I","headline":"A Blueprint for Action: Michigan’s Lawsuit Against Express Scripts and Prime Therapeutics Signals a Turning Point for In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPbURfWmFFeU5FSk1IN1pOLUtLazFKN1hLd3ZRUzlFZGdRNTRyX2Rab2FPdzhDcG1rbjQ1bnlGRHZEa2Rodkt4ZEpDdFQ0QVpwZUVZT0ZsNllGWTV0a2lzeGNvQ0JBdmpCbnZkbHNFYzNGQlFRdlN0S0hPeEV4ZnpQQlpJM0l0aXEtZ1VfUlp1aUhNNUVmQll1cGhlYVd2ZUM2U05ib283djJnVl9sWHI5WUdB?oc=5","date":"2023-11-16","type":"regulatory","source":"Fierce Pharma","summary":"Bristol Myers' $4.1B Turning Point buy yields FDA approval for lung cancer drug Augtyro - Fierce Pharma","headline":"Bristol Myers' $4.1B Turning Point buy yields FDA approval for lung cancer drug Augtyro","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNbnpDcEVHc0dMdVFhWHFSSWs4MkEyT0JOVTIyeWd0blBZY2R4cTNQS3VfSjFSN1VtX2Q3OGVxV0Nia2ZSM3B4bDU3Sm1ibi1ERzJ5NWNZaEZHYWJ3ekg2SlZZQlIyeklvWmN6TU1ROXo3NHBpWW94RmMybXpELTdWNnpnMm5qN2cyWFp2MnR0WDgzQ1RIVWNtbQ?oc=5","date":"2022-06-03","type":"deal","source":"Fierce Biotech","summary":"UPDATE: Bristol Myers strikes up Roche rivalry with $4.1B Turning Point buy - Fierce Biotech","headline":"UPDATE: Bristol Myers strikes up Roche rivalry with $4.1B Turning Point buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNTWYya3daNnlWY2sxMFdnS09md01RTHlmZmZrb0ZUSFFrcGFxR0UtbVRqX1A3RWpTNVJBQ2Y5cXVNU3NuaFltbmFCMXZybDVSQ1pWa2ZCTl9fbnI0dHlweFVYOU1IYzQ4S0ZVaGt3dHA0aWRjWWFPSTRMTndqTzE0dWZ6QjNrUGVxcmFlMk9lclZRVnE2SXAyTnc1am4yaFBOT0U3OF9VT3RXM1B0NS1J?oc=5","date":"2022-06-03","type":"deal","source":"Reuters","summary":"Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning Point deal - Reuters","headline":"Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning Point deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQbWVqUTRVMFdZZ1RqQ2xPQlQ1bWxKRlRNTDNSb3dVd1p0d25YWUlFZVFTRk1mYVJLV1lyTmlENjl1dzBQbUdkNDNTZGR0ZjRmV0xlNWY2TElzRlNPU1BlaXdwRUZnRlBQYjloUzBGVkxzVE1sSlgxZUFzMkZUcnZNSGlrTC1YN1JFeEZ6Z0lYUm5SNGpzSUUzR1dzV1BUQmhRazNaZXd2am1YMHBROFE?oc=5","date":"2022-06-03","type":"deal","source":"wsj.com","summary":"Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion - wsj.com","headline":"Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNNTA4aGFBWHR5RlNQQXVDSjJIQjE5RXNGbG5vMDFHZGUzTEZ6ejBfVU5CSUZtbDM1Z28xLXpVZ2RWcjNKaFY0WkpXMURsNU1OUFcwX042MkJqbGVRc00zaGVCSng1QWFsNUdnTlZOSTREcktRV3ktZUhPTk0wLWVZYlVxNFU3VmVuUnRtQkhLZ2l2VUVnUG9ITGNmUjNrelFOWkJSNTFvaVdRN1hYSjRNMg?oc=5","date":"2022-06-03","type":"pipeline","source":"BioPharma Dive","summary":"Bristol Myers bets $4B on Turning Point and its targeted cancer drugs - BioPharma Dive","headline":"Bristol Myers bets $4B on Turning Point and its targeted cancer drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOOC1WOUstSTJUckhSUmdBcnVNNUF5N19sTXkyX1lBbEY4TWJ0eTJVMTdPUUlOSGlDcXdSbHhmNllPTVRsM1FoV1h6YnRxdjNwWDVkd00xSGdkQnpBa0JLSUlqaG9sWVdZbzVvbmwyNmpoaUdvcFhITEhjU2VINTRyMjhDNFNjV3ZvYkRoNE1SVVBLNjRxYkZMV1BwMWpibVZsdlpoTjFPZTB6bm54a0N1OFNyOHV5M2ZiWFRaNmJUTGdQYW9RdDZYdTN3Qkx4MWxrbDBVbENCMjNRUkxzcnZla1ZhdTFneU9X?oc=5","date":"2022-06-03","type":"deal","source":"statnews.com","summary":"Bristol Myers Squibb to buy Turning Point Therapeutics for $4.1 billion to gain drugs targeting rare cancer mutations - statnews.com","headline":"Bristol Myers Squibb to buy Turning Point Therapeutics for $4.1 billion to gain drugs targeting rare cancer mutations","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}